Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05652894 |
TitleA Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | 阶段
第三阶段
|
Date Added 2022-12-15 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
HX008, Investigator's Choice Chemotherapy |
标签
MSI-H/ MMRd
|
| NCT ID NCT05672316 |
TitleBotensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | 阶段
第 1 阶段
|
Date Added 2023-01-05 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, Regorafenib |
标签
MSS/ MMRp
|
| NCT ID NCT05673148 |
TitleERASur研究：测试在有限转移性结直肠癌的常规系统疗法基础上增加全烧蚀疗法的效果 | 阶段
第三阶段
|
Date Added 2023-01-06 |
地点
Arizona, United States
California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Maryland, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Dakota, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
化疗 |
标签
MSS/ MMRp
|
| NCT ID NCT05677113 |
TitleA Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver | 阶段
第二阶段
|
Date Added 2023-01-10 |
地点
加拿大
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Placebo, QBECO |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05676190 |
TitleClinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer | 阶段
不适用
|
Date Added 2023-01-09 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05608044 |
TitleA Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases | 阶段
第二阶段
|
Date Added 2022-11-08 |
地点
Arizona, United States
California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States 比利时 巴西 法国 格鲁吉亚 意大利 Russian Federation 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, Regorafenib, TAS-102 |
标签
MSS/ MMRp
|
| NCT ID NCT05609370 |
TitleA Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-11-08 |
地点
Alaska, United States
Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States 澳大利亚 中国 波多黎各 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, capecitabine, LBL-007, Tislelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT05425940 |
TitleStudy of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) | 阶段
第三阶段
|
Date Added 2022-06-21 |
地点
Alabama, United States
Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States 澳大利亚 比利时 法国 德国 香港 Hungary 大韩民国 新西兰 波兰 葡萄牙 新加坡 西班牙 台湾 泰国 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT05627635 |
TitleFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-11-25 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT05328908 |
Title一项针对转移性结直肠癌晚期患者的 Nivolumab-relatlimab 固定剂量联合疗法对比瑞戈非尼或 TAS-102 的研究 | 阶段
第三阶段
|
Date Added 2022-04-14 |
地点
Arkansas, United States
California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States 阿根廷 澳大利亚 Austria 比利时 加拿大 智利 中国 Czechia 法国 德国 意大利 日本 大韩民国 荷兰 波兰 波多黎各 新加坡 西班牙 瑞典 瑞士 台湾 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga |
标签
MSS/ MMRp
|
